• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Another BD Alaris infusion pump recall is Class I

April 16, 2021 By Sean Whooley

BD-logo-newThe FDA has identified another recall for the Alaris infusion pump from BD (NYSE:BDX) as Class I, the most serious kind of recall.

BD’s latest recall, initiated on March 3, 2021, involves its BD Alaris infusion pump module system, which includes an infusion pump and vital signs monitoring system with a PC unit, the Guardrails Suite MX and up to four removable infusion or monitoring modules (channels), according to an FDA notice.

CareFusion 303 Inc. is recalling the Alaris pump module because there is a risk of the keypad lifting up due to fluid entry, an issue that could result in keys that become unresponsive or stuck. That could lead to an infusion delay or interruption, or it could prevent clinicians from changing fluid or medication infusions on the affected devices. Such delays or interruptions could cause serious injury or death.

To date, there have been 79 complaints regarding the device issue, but no reports of injuries or death. The recall is separate from an August recall of the Alaris pump module 8100 keypad for stuck keys, though BD spokesperson Troy Kirkpatrick tells Drug Delivery Business News and MassDevice that devices remediated in the August recall do not need remediation a second time.

Affected products in the latest recall were manufactured between Jan. 15, 2019, and Dec. 5, 2019, and distributed between Jan. 23, 2019, and Dec. 5, 2019. So far, 145,492 devices have been recalled in the U.S. Kirkpatrick said the cause involved a supplier manufacturing issue.

Franklin Lakes, N.J.–based BD has had shipments of Alaris pumps on hold since 2020 after the FDA called for a comprehensive 510(k) submission to cover a host of software fixes needed after a different Class I-level recall. Pumps are only going to health providers with an immediate medical need.

In November, the company disclosed that it set aside $244 million to cover future product remediation costs, including its effort to fix the problematic Alaris pumps.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Recalls, Regulatory/Compliance Tagged With: BD, Becton Dickinson, FDA

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS